Uncategorized Archives - Page 6 of 87 - PsychedelicNewsWire (PNW)

TuesdayOct 25, 2022 12:39 pm

Survey Finds No Link Between Psychedelics Use, Cancer Risk

New research has found that the use of psychedelic substances is not linked to the lifetime development of cancer. The investigators’ objective was focused on determining whether there was any truth to research from the 1960s that associated the use of psychedelics to a heightened risk of developing cancer. The research in question was conducted in 1967, with those involved reporting that the use of LSD caused chromosomal damage in white blood cells. Subsequent studies also suggested that exposure to LSD could have carcinogenic potential. For their study, the researchers focused on expanding on a 2021 study that explored the…

MondayOct 24, 2022 10:30 am

Silo Pharma Inc.’s (NASDAQ: SILO) Novel Ketamine Formulation Undergoing Safety Evaluation, Pursuing Regulatory Pathway

Ketamine used for decades in large doses for surgical anesthesia, low-dose treatments currently prescribed for pain relief, sedation, and treatment-resistant depression Silo’s time-released ketamine formulation SP-26 currently undergoing safety evaluation, study to uncover maximum tolerated dosing data for future trials SP-26 previously reported positive results in reducing neuropathic nerve pain Silo preparing FDA Pre-Investigational New Drug (“IND”) package for SP-26, intends to pursue 505(b)(2) regulatory pathway Ketamine was approved in the United States in 1970 and has been used extensively for surgical anesthesia. Since then, use of the drug in small doses has expanded considerably to treat pain and treatment-resistant…

WednesdayOct 19, 2022 11:28 am

Study Finds That MDMA May Be Useful in Treating Eating Disorders

An eating disorder is a severe mental health condition that may have damaging emotional and physical consequences for the sufferer. Common eating disorders include bulimia nervosa, binge-eating disorder, and anorexia nervosa. New research has found that MDMA-assisted therapy decreased symptoms of eating disorders in adults suffering from severe PTSD. MDMA, which is commonly known as ecstasy, has demonstrated promise in the treatment of a range of mental health conditions, especially when administered in combination with other therapeutic interventions. The FDA recently granted breakthrough therapy designation for MDMA-assisted therapy for post-traumatic stress disorder, recognizing that it had shown significant improvement over…

WednesdayOct 05, 2022 10:30 am

Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market

Silo Pharma, Inc recently uplisted to the Nasdaq Capital Market, raising gross proceeds of $5 million The biopharmaceutical company has sought to merge traditional therapeutics and psychedelic research, entering into a series of joint ventures with leading medical universities to carry out research into the field Meanwhile, psychedelics are gaining increasing favour within the United States with Oregon set to begin allowing the supervised usage of psilocybin from 2023 onwards Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had successfully priced its fully underwritten initial public offering,…

TuesdaySep 27, 2022 12:00 pm

Ancillary Firms to Play Bigger Role in Psychedelics Space

For a while now, researchers have been conducting studies on psychedelics, gathering more knowledge on these substances and their benefits. Prior research has demonstrated that psychedelics could help manage anxiety, treatment-resistant depression and post-traumatic stress disorder for individuals who haven’t benefitted from the currently prescribed medications. As the psychedelics space grows, so do investments into the market. Unsurprisingly, the number of nondrug startups involved in the space has increased considerably, moving from 19% in 2020 to 38% in 2021. However, with the market reaching oversaturation and funding for biotech startups drying up, many believe that ancillary tech firms will be…

MondaySep 26, 2022 12:00 pm

An Analysis of Psychedelics in End-of-Life Care

Psychedelics are slated to disrupt psychiatry in a major way. Although there is limited research on the possible benefits of hallucinogenic drugs, recent studies have found that they can have significant mental health benefits. Researchers have discovered that when paired with psychotherapy, psychedelics can deliver profound benefits for people with mental health conditions, including PTSD, anxiety, depression and eating disorders. Specifically these mental health benefits, especially against anxiety and depression, can come in handy for patients in palliative or end-of-life care. Receiving a terminal diagnosis often results in feelings of grief, anxiety and depression. According to researchers from Baylor University…

FridaySep 23, 2022 11:15 am

Researchers Investigate Whether Psilocybin Mushrooms Can Help Combat Obesity

Psilocybin is the primary active compound found in hallucinogenic mushrooms. This compound usually turns into psilocin upon consumption. Recent research has provided evidence showing that psilocybin-assisted therapy may be effective in treating addiction, which has led others to wonder whether the psychedelic could also help individuals to control food cravings. A 2021 study also found that individuals who had ingested a classic psychedelic at least once in their lives had a considerably lower chance of being obese or overweight. These findings prompted a group of investigators to begin conducting research on whether psilocybin could help treat eating disorders and obesity.…

TuesdaySep 20, 2022 12:00 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

First dose is administered as first-ever novel psilocybin analog enters clinical development Cybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybin The high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective therapeutics. The company is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. Late last month, the first two trial participants…

WednesdayAug 31, 2022 11:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin After receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (https://ibn.fm/jV5o9), showing promise in treating alcohol addiction with the psychedelic compound psilocybin. This news aligns with initiatives of Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, which has a drug in development, CYB003, for the treatment of alcohol…

FridayAug 26, 2022 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain's connectivity patterns CYBN is leading the industry in developing proprietary psychedelic-based therapeutics The company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin (NEO: CYBN) (NYSE American: CYBN) is on the leading edge of this transformation, as the clinical-stage biopharmaceutical company focuses on progressing psychedelics to therapeutics by offering a new standard of care for mental-health disorders…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized